within Pharmacolibrary.Drugs.ATC.R;

model R03AL04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00038833333333333336,
    adminDuration  = 600,
    adminMass      = 110 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.37,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 1.58,
    k12             = 1030,
    k21             = 1030
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AL04</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Indacaterol and glycopyrronium bromide, under the ATC code R03AL04, is a fixed-dose combination inhalation therapy used in the treatment of chronic obstructive pulmonary disease (COPD) to improve lung function and reduce exacerbations. Indacaterol is a long-acting beta2-adrenergic agonist (LABA), while glycopyrronium is a long-acting muscarinic antagonist (LAMA). The combination is approved and in use for maintenance treatment of COPD in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following inhalation. Parameters refer to steady-state or single-dose studies. Both drugs are administered together via inhalation in a fixed-dose combination.</p><h4>References</h4><ol><li><p>Vaidya, S, et al., &amp; Tillmann, HC (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. <i>Pulmonary pharmacology &amp; therapeutics</i> 64 101964–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2020.101964&quot;>10.1016/j.pupt.2020.101964</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33035700/&quot;>https://pubmed.ncbi.nlm.nih.gov/33035700</a></p></li><li><p>Ren, S, et al., &amp; Zhao, R (2017). Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 55(2) 147–155. DOI:<a href=&quot;https://doi.org/10.5414/CP202640&quot;>10.5414/CP202640</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27841152/&quot;>https://pubmed.ncbi.nlm.nih.gov/27841152</a></p></li><li><p>Prakash, A, et al., &amp; Morjaria, JB (2015). Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. <i>International journal of chronic obstructive pulmonary disease</i> 10 111–123. DOI:<a href=&quot;https://doi.org/10.2147/COPD.S67758&quot;>10.2147/COPD.S67758</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25609944/&quot;>https://pubmed.ncbi.nlm.nih.gov/25609944</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AL04;
